Development and validation of the first digital, clinical grade flow cytometry platform for enhanced diagnosis accuracy and sustainability in immunology and hemato oncology

After successful development of METAglut1, an IVD Medical Device for diagnosis of the Glut1 Deficiency Syndrome ( available for clinical use), we are currently focused on developing a new breakthrough solution: METAflow. Flow cytometry (FC) is a powerful tool widely use in research. However, the high cost and complexity of interpretation of FC data hampers its full clinical exploitation.

Main pain-points of clinical FC data analysis, include need for manual analysis, which is accompanied by complexity with increasing number of dimensions, lack of robustness and limited scale-up.

The lack of automated analytical process stems from dearth of robust algorithms, limited regulatory compliance and need for considerable coding skills.

With METAflow we bring to the market the first digital, clinical grade FC platform, which offers comprehensive data analysis, robustness, and usability, addressing the “lost in translational research” issue of flow cytometry in the clinics.